» Articles » PMID: 37221610

Identification of BRAF, CCND1, and MYC Mutations in a Patient with Multiple Primary Malignant Tumors: a Case Report and Review of the Literature

Overview
Publisher Biomed Central
Date 2023 May 24
PMID 37221610
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Multiple primary malignant tumors (MPMTs), usually associated with worse malignant behavior and prognosis comparing to a single primary tumor, and have recently been found to have an increasing incidence globally. However, the pathogenesis of MPMTs remains to be clarified. Here, we report a unique case of the coexistence of malignant melanoma (MM), papillary thyroid carcinoma (PTC), and clear-cell renal cell carcinoma (ccRCC) along with our perceptions on its pathogenesis.

Case Presentation: The case reported is of a 59-year-old male patient with unilateral nasal obstruction as well as a renal occupying lesion. Positron emission tomography-computed tomography (PET-CT) revealed a palpable mass of 32 × 30 mm on the posterior and left walls of the nasopharynx. In addition, an isodense nodule was observed in the right superior renal pole, approximately 25 mm in diameter, as well as a slightly hypodense shadow in the right leaf of the thyroid, approximately 13 mm in diameter. Nasal endoscopy and magnetic resonance imaging (MRI) confirmed the existence of a nasopharyngeal neoplasm. Afterward, biopsies of the nasopharyngeal neoplasm, thyroid gland and kidney were performed, and the patient was diagnosed with MM, PTC, and ccRCC according to the pathological and immunohistochemical results. Moreover, mutation of BRAF was detected in bilateral thyroid tissues, and amplification of both CCND1 and MYC oncogenes were detected in the nasopharyngeal melanoma. After chemotherapy, the patient is now in good overall condition.

Conclusions: This is the first reported case of a patient with the co-existence of MM, PTC and ccRCC undergoing chemotherapy with a favorable prognosis. Herein, we suggest that such a combination may be non-random, as for mutation of BRAF might account for the co-occurrence of PTC and MM, while mutations of CCND1 and MYC cause the coexistence of MM and ccRCC. This finding may provide valuable guidance on the diagnosis and treatment of such disease, as well as the prevention of developing a second or third tumor for patients with a single primary.

Citing Articles

Durable response to nivolumab rechallenge in a patient with metastatic clear cell renal cell carcinoma.

Fujiwara M, Shimada W, Yokoyama M, Koyanagi A, Shintaku H, Fukuda S IJU Case Rep. 2024; 7(4):293-296.

PMID: 38966764 PMC: 11221937. DOI: 10.1002/iju5.12727.


Synchronous double primary small cell lung cancer and invasive ductal breast carcinoma: a case report.

Gan J, Liu M, Liu F, Wen J, Fu W, Jia J BMC Pulm Med. 2024; 24(1):93.

PMID: 38388422 PMC: 10885399. DOI: 10.1186/s12890-024-02897-y.

References
1.
Qian Y, Li Y, Xu L, Chen K, Liu N, Yang X . Tumor Cell-Derived Exosomal circ-PRKCI Promotes Proliferation of Renal Cell Carcinoma via Regulating miR-545-3p/CCND1 Axis. Cancers (Basel). 2023; 15(1). PMC: 9817713. DOI: 10.3390/cancers15010123. View

2.
Cheli Y, Ohanna M, Ballotti R, Bertolotto C . Fifteen-year quest for microphthalmia-associated transcription factor target genes. Pigment Cell Melanoma Res. 2009; 23(1):27-40. DOI: 10.1111/j.1755-148X.2009.00653.x. View

3.
Kubecek O, Kopecky J . Microsatellite instability in melanoma: a comprehensive review. Melanoma Res. 2016; 26(6):545-550. DOI: 10.1097/CMR.0000000000000298. View

4.
Oakley G, Curtin K, Layfield L, Jarboe E, Buchmann L, Hunt J . Increased melanoma risk in individuals with papillary thyroid carcinoma. JAMA Otolaryngol Head Neck Surg. 2014; 140(5):423-7. DOI: 10.1001/jamaoto.2014.78. View

5.
Shah M, Orengo I, Rosen T . High prevalence of hypothyroidism in male patients with cutaneous melanoma. Dermatol Online J. 2006; 12(2):1. View